Eton Pharmaceuticals Inc (ETON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) has a cash flow conversion efficiency ratio of 0.156x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($7.25 Million) by net assets ($46.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Eton Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
Eton Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Eton Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eton Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eton Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Eton Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tecnoglass Inc
NYSE:TGLS
|
0.006x |
|
Yangling Metron New Material Co Ltd
SHE:300861
|
-0.003x |
|
CIE Automotive India Limited
NSE:CIEINDIA
|
0.172x |
|
C3 Ai Inc
NYSE:AI
|
-0.081x |
|
Hangzhou Shunwang Tech
SHE:300113
|
0.044x |
|
Henan Lingrui Pharmaceutical Co Ltd
SHG:600285
|
0.038x |
|
Guizhou Aviation Technical Development Co Ltd
SHG:688239
|
-0.531x |
|
Hansol Chemica
KO:014680
|
0.061x |
Annual Cash Flow Conversion Efficiency for Eton Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Eton Pharmaceuticals Inc from 2017 to 2025. View ETON stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.15 Million | $10.52 Million | 0.402x | +914.39% |
| 2024-12-31 | $24.43 Million | $969.00K | 0.040x | -90.99% |
| 2023-12-31 | $15.48 Million | $6.82 Million | 0.440x | +19.45% |
| 2022-12-31 | $13.08 Million | $4.82 Million | 0.369x | +237.66% |
| 2021-12-31 | $17.63 Million | $-4.72 Million | -0.268x | +81.23% |
| 2020-12-31 | $15.66 Million | $-22.35 Million | -1.427x | +16.50% |
| 2019-12-31 | $10.55 Million | $-18.03 Million | -1.709x | -451.77% |
| 2018-12-31 | $26.30 Million | $-8.14 Million | -0.310x | +20.39% |
| 2017-12-31 | $12.13 Million | $-4.72 Million | -0.389x | -- |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for … Read more